BOSTON, Feb. 26, 2004 (PRIMEZONE) -- NeuroSystems, LLC announced today that it has filed an additional U.S. patent for its Multimodality NeuroMonitoring technology.
Building on the company's existing base of intellectual property, the present filing describes a suite of unique, tunable algorithms which analyze and display higher order relationships between and among basic monitored parameters such as intracranial pressure (ICP), cerebral blood flow (CBF), blood pressure, and the partial pressures of oxygen and carbon dioxide.
While neurosurgical monitoring has historically been largely limited to the measurement of ICP, a rather late stage indicator of the patient's status and probable clinical outcome, the past decade has seen the introduction of a number of sensor technologies which permit the monitoring of other important physical and chemical quantities including CBF, tissue oxygen and carbon dioxide, pH, temperature, and the concentrations of various metabolites and ions via microdialysis. According to NeuroSystems, with the recent exception of CBF, there has been little effort to interrelate these new data in real-time in clinically meaningful ways. As a result, many potentially important monitored parameters have to date been underutilized.
By intelligently blending various individual parameters, the company's first product, NeuroSystems 1(tm), will provide neurosurgeons and other clinicians the ability to display important higher order, clinically relevant neurophysiologic functions including cerebral autoregulation, vasoreactivity and oxygen metabolism via a series of full-featured clinician displays.
According to Walter Johnson, MD, Associate Professor of Vascular Neurosurgery at Loma Linda University Medical Center, "Multimodality neuromonitoring will soon be the standard of care in neurotrauma and cerebrovascular disease critical care. With the addition of new parameters like oxygen saturation and cerebral blood flow, we need new ways of looking at these data and their relationship with other physiologic parameters, continuously and in real-time. "
Rick Cataldo, NeuroSystems' Vice President of Sales & Marketing, added, "It is clear that the successful integration of new parameters into the neuromonitoring regime is directly related to the ability to analyze interrelated data and display data relationships in a clinically useful format. NeuroSystems 1 represents a decisive step forward in multimodality neuromonitoring."
NeuroSystems' mission is to develop and market intelligent NeuroMonitoring systems which maximize the clinical value of basic monitored parameters through real-time calculation, storage and display of clinically relevant derived parameters and neurophysiologic indicators.
-- CAUTION: Investigational Device. Limited by Federal (USA) law to investigational use.